EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Melatonin in the treatment of Circadian Rhythm Sleep-Wake Disorders – the principles of choosing the right time and dose of administration

Adam Wichniak, Aleksandra Wierzbicka, Katarzyna Gustavsson, Joanna Szmyd, Wojciech Jernajczyk

Pharmacotherapy in Psychiatry and Neurology · 2019

DOI: 10.33450/fpn.2019.01.002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacotherapy in Psychiatry and Neurology, 2019. Verfasst von Adam Wichniak und 4 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Circadian Rhythm Sleep-Wake Disorders (CRSWD) are a common group of sleep disorders. The aim of this article is to present the principles for treatment of CRSWD with melatonin.

Methods

Review of data from randomised, placebo-controlled clinical trials.

Results

The main indication for the use of melatonin is a treatment of Delayed Sleep-Wake Phase Disorder (DSWPD). Melatonin is also recommended for the treatment of Irregular Sleep-Wake Rhythm Disorder and Non-24-Hour Sleep-Wake Rhythm Disorder. However, in the treatment of Advanced Sleep-Wake Phase Disorder melatonin plays a secondary role. The therapeutic effect of melatonin primarily depends on the appropriate time of its administration. In DSWPD it should be administered even 6–8 hours before the scheduled sleep time. The available data does not indicate that the melatonin’s therapeutic effect is strongly correlated with the used dose and the recommended doses fall within a wide range of 0.5 to 10 mg. However, usually higher doses, e.g. 5 mg, are beneficial in the first 3–6 weeks of treatment. In neuropsychiatric disorders in children, dosage even up to 10 mg is recommended. Melatonin is also an effective form for relieving symptoms of exogenous CRSWD: shift work disorder and jet lag disorder. Prolonged-release formulation of melatonin in a 2 mg dose is registered for the treatment of insomnia patients aged 55 years and older.

Conclusions

Treatment of CRSWD is based primarily on chronotherapeutic interventions. They include phototherapy, light avoidance, melatonin treatment and behavioural interventions that influence, among other things, the rhythm of meals, physical and social activity.

Zitieren

APA

Wichniak, A., Wierzbicka, A., Gustavsson, K., Szmyd, J., & Jernajczyk, W. (2019). Melatonin in the treatment of Circadian Rhythm Sleep-Wake Disorders – the principles of choosing the right time and dose of administration. Pharmacotherapy in Psychiatry and Neurology. https://doi.org/10.33450/fpn.2019.01.002

Vancouver

Wichniak A, Wierzbicka A, Gustavsson K, Szmyd J, Jernajczyk W. Melatonin in the treatment of Circadian Rhythm Sleep-Wake Disorders – the principles of choosing the right time and dose of administration. Pharmacotherapy in Psychiatry and Neurology. 2019. doi:10.33450/fpn.2019.01.002

BibTeX
@article{Wichniak2019,
  author = {Wichniak, Adam and Wierzbicka, Aleksandra and Gustavsson, Katarzyna and Szmyd, Joanna and Jernajczyk, Wojciech},
  title = {Melatonin in the treatment of Circadian Rhythm Sleep-Wake Disorders – the principles of choosing the right time and dose of administration},
  journal = {Pharmacotherapy in Psychiatry and Neurology},
  year = {2019},
  doi = {10.33450/fpn.2019.01.002}
}
Kostenlos starten →